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The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is 
continuously evolving due to new treatment options and our increasing knowledge of 
molecular signal pathways. As a result of treatments becoming more efficacious and 
more personalized, survival for selected groups of non-small cell lung cancer (NSCLC) 
patients is increasing. In this paper, three algorithms will be presented for treating 
patients with metastatic non-squamous, NSCLC. These include treatment algorithms 
for NSCLC patients whose tumors have EGFR mutations, ALK rearrangements, or wild-
type/wild-type tumors. As the world of immunotherapy continues to evolve quickly, a 
future algorithm will also be presented.
Keywords: metastatic non-squamous non-small cell lung cancer, systemic therapy, chemotherapy, targeted 
therapy, epidermal growth factor receptor, anaplastic lymphoma kinase, algorithm
inTRODUCTiOn
The previous standard of care in metastatic non-small cell lung cancer (NSCLC) was to treat patients 
with a platinum doublet for four to six cycles and to offer second-line therapy upon progression (1).
The emergence of molecular tests allows us to tailor treatment strategies based on the presence of 
driver mutations. Patients who have genetic alterations to epidermal growth factor receptor (EGFR) 
and anaplastic lymphoma kinase (ALK) now benefit from targeted therapies in the first line and 
beyond. In patients with no known driver mutations, the efficacy of immunotherapy with checkpoint 
inhibitors has revolutionized treatment. This area is evolving rapidly.
As new treatment options emerge, algorithms must balance the need to give the best drugs first 
with ensuring that there are still beneficial options available for later. The treatment algorithms 
discussed in this paper are based on Canadian recommendations. Although other health authorities 
may have different therapeutics available, many basic principles apply.
This paper discusses treatments for patients with non-squamous histology only.
Tumor mutation testing allows us to divide patients into three groups: patients with EGFR-positive 
tumor mutations (10–30%) (2); patients with ALK rearrangements (4–7%) (2); and patients with 
tumors who either do not have EGFR or ALK mutations, or their mutation status is unknown. As 
mutation testing expands to include new targets including human epidermal growth factor receptor 
2 (HER2), BRAF, RET and MET and effective treatments are found, the treatment algorithms will 
increase in complexity (3).
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HR, hazard ratio; HER 2, human 
epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; OS, overall survival; ORR, overall response rate; RR, 
response rate; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
FigURe 1 | Treatment algorithms for non-small cell lung cancer (nSCLC) patients whose tumors have driver mutations. (A) A treatment algorithm for 
patients with EGFR-positive metastatic, non-squamous NSCLC [adapted from Melosky, Popat, and Gandara (submitted)]. (B) A treatment algorithm for patients with 
ALK-positive metastatic, non-squamous NSCLC.
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egFR MUTATiOn POSiTive
First-line Therapies: Tyrosine Kinase 
inhibitors
Tyrosine kinase inhibitors (TKIs) that inhibit the EGFR are 
now standard of care for first-line treatment in patients with 
metastatic, non-squamous NSCLC whose tumors harbor an 
EGFR mutation (Figure 1A). Randomized trials have shown that 
patients experience superior overall response rates (ORR) and 
progression-free survival (PFS) when treated with EGFR TKIs 
versus chemotherapy for first-line therapy [erlotinib: EURTAC 
(4), OPTIMAL (5); gefitinib: NEJGSG_ 002 (6), WJTOG 3405 
(7), IPASS (8, 9); afatinib: LUX LUNG 3 (10, 11), LUX LUNG 6 
(11, 12)].
Erlotinib and gefitinib are first generation TKIs, while afatinib 
is a second generation TKI. Second generation TKIs block more 
ligands of the HER family and are non-competitive inhibitors at 
the kinase site so confer a longer period to resistance (13). Patient 
performance status, comorbidities, and age come into play in the 
decision making. EGFR mutation subtype is also important to 
consider. Unlike chemotherapy, TKIs are continued past progres-
sion as long as there is a clinical benefit to the patient.
LUX LUNG 7, a recently reported randomized phase IIb trial, 
compared afatinib to gefitinib in patients with advanced NSCLC 
and common EGFR mutations (14). The coprimary endpoint 
of PFS hazard ratio (HR) was met for superiority of afatinib, 
HR = 0.73 (p = 0.0165). This benefit was independent of muta-
tion subtype. Response rate (RR), a secondary endpoint, was 70% 
versus 56% (HR = 1.873, p = 0.0083) favoring afatinib. Toxicities 
were as expected, with a preponderance of diarrhea and rash 
for afatinib and transaminitis for gefitinib. The overall survival 
(OS) was 3 months longer for afatinib (27.9 versus 24.5 months) 
but did not meet statistical significance [HR: 0.86 (95% CI: 
0.66–1.12), p = 0.2580] (15). ARCHER 1050, a 452 patient phase 
III randomized trial of first-line treatment of EGFR-positive 
NSCLC comparing gefitinib with dacomitinib, will shed light on 
the question of which EGFR TKI is superior (16).
The inhibition of both EGFR and angiogenesis pathways 
deserves comment. The results of a randomized phase II trial 
from Japan illustrated a benefit for the combination erlotinib–
bevacizumab over erlotinib for common EGFR mutations (17). 
Median PFS for the combination was 16.0 versus 9.0  months 
for erlotinib monotherapy, with no statistical difference in RRs 
or OS (18). In June 2016, the European Commission approved 
the combined use of erlotinib and bevacizumab for the first-line 
treatment of EGFR positive NSCLC patients. A larger phase III 
trial of this EGFR TKI–bevacizumab combination is needed to 
confirm and quantify the benefit (18).
Retesting for egFR Mutations  
on Progression
An acquired mutation in EGFR exon 20, T790M, which leads to 
drug resistance, may be found in up to 60% of patients progress-
ing on TKIs (19). Repeat testing for mutations is now recom-
mended. Testing plasma cell free (cf) DNA has been suggested 
as an alternative to repeat biopsy. Different testing platforms are 
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being developed and validated, and concordance between cfDNA 
and tumor tissue is improving (20–23). Patients who initially test 
negative for the presence of a T790M mutation by cfDNA testing 
should undergo a tumor rebiopsy. Biopsy is still considered to be 
the gold standard for T790M molecular testing.
Second-line Therapy
For patients with a T790M positive disease, third generation 
EGFR TKIs have demonstrated RRs of over 60% and prolonged 
PFS, resulting in the approval of osimertinib (AZD9291) in 
several countries. Pooled results from AURA phase I and II trials 
was recently presented, which evaluated osimertinib in patients 
with T790M-positive disease who progressed on previous EGFR 
TKIs (24). Patients from the pooled cohort (n = 411) had a RR of 
66%, and a PFS of 11 months (24, 25).
For patients without a T790M, second-line therapy is a chemo-
therapy doublet. Patients who are T790M mutation negative 
who progress on chemotherapy have few other options and may 
consider a clinical trial.
ALK MUTATiOn POSiTive nCSLC
Rearrangements in the ALK gene are found in adenocarcinomas 
and more commonly in light or non-smokers. ALK rear-
rangements occur in approximately 4–7% of lung cancers (2). 
A treatment algorithm for patients with ALK-positive metastatic, 
non-squamous NSCLC is shown in Figure 1B.
First-line Therapy with Crizotinib
For patients whose tumors are positive for an ALK rearrange-
ment, crizotinib is superior to standard chemotherapy. The 
phase III PROFILE 1014 trial randomized 343 treatment-naïve 
patients with advanced ALK rearrangement positive NSCLC to 
receive either crizotinib or intravenous chemotherapy (26). The 
primary endpoint of PFS was significantly longer in patients 
treated with crizotinib at 10.9  months as compared to those 
treated with chemotherapy at 7.0  months [HR: 0.45 (95% CI: 
0.35–0.60); p < 0.001]. Overall RRs were 74% for crizotinib and 
45% for chemotherapy (p < 0.001). Median OS was not reached 
in either group due to cross-over [HR: 0.82 (95% CI: 0.54–1.26); 
p = 0.36] (26). Crizotinib was associated with a greater reduc-
tion in symptoms and better quality of life. As with other TKIs, 
crizotinib can be continued past progression if there is continuing 
clinical benefit to the patient.
Second-line Therapy with Ceritinib, 
Alectinib, or Brigatinib
New agents are proving valuable as second-line treatments 
for NSCLC patients with ALK-positive tumors. As the brain 
is a frequent site of metastasis for patients with ALK-positive 
tumors, the intracranial activity of these agents is important 
to consider.
Ceritinib
Ceritinib is a second-generation ALK inhibitor that has demon-
strated impressive RRs and has improved survival in patients who 
have progressed on crizotinib. The results of the ASCEND 1, 2, 
and 3 trials demonstrated the efficacy of ceritinib in treating both 
systemic disease and brain metastasis.
The ASCEND 1 phase I trial evaluated the efficacy and safety 
of ceritinib in 246 patients with advanced ALK-positive NSCLC 
(27). The ORR for all patients was 61.8%; 56.4% in pretreated 
patients and 72.3% in inhibitor-naïve patients. The PFS was 
6.9 months for all trial participants (28). Of the 28 subjects with 
measurable brain metastases at baseline, 35% (n =  10) had a 
partial response (29). As a result of this trial, the FDA approved 
ceritinib for patients with advanced ALK-positive NSCLC follow-
ing treatment with crizotinib in April 2014.
The ASCEND 2 single-arm phase II trial evaluated ceritinib 
efficacy in patients with advanced ALK-positive NSCLC who had 
progressed on both standard chemotherapy and crizotinib. With 
an ORR of 38.6% and a PFS of 5.7 months, ASCEND 2 confirmed 
the efficacy of ceritinib (30).
The ASCEND 3 single-arm phase II trial evaluated ceritinib 
efficacy in treatment-naïve patients with advanced ALK-positive 
NSCLC (31). In this trial, PFS was 11.1  months, with a RR of 
36.3%. ASCEND 3 demonstrated that ceritinib has intercranial 
activity; a blinded independent central review demonstrated a 
58.8% intracranial response in 50 (40.3%) of subjects with brain 
metastases (31).
Alectinib
Alectinib, another second-generation ALK inhibitor, also dem-
onstrated impressive RRs and has improved survival in patients 
who have progressed on crizotinib. A phase I/II trial first evalu-
ated the efficacy of alectinib in patients with crizotinib-refractory 
ALK-positive NSCLC; the dose determined in the phase I com-
ponent was 600 mg orally twice a day (32). Two large phase II 
trials conducted in North America and internationally evaluated 
the efficacy and safety of alectinib in patients with ALK-positive 
NSCLC who had progressed on crizotinib. In the international 
study, an ORR of 50.8% was observed, the CNS ORR was 58.8% 
with 20.6% complete responses (33). In the North America trial, 
similar results were seen with an ORR of 52.2%. The CNS ORR 
in patients with measurable CNS metastases was 75%, with 25% 
complete responses (34). In both studies, Grade  ≥  3 adverse 
events were rare (33, 34).
Japanese researchers have studied alectinib in the first-line set-
ting. The AF-001JP phase I study conducted in ALK treatment-
naïve patients showed impressive efficacy. Because Japan has 
regulations on the use of sodium lauryl sulfate, the dose was set 
at just 300 mg twice daily (35).
Primary results of the phase III J-ALEX trial were presented 
at the 2016 American Society of Clinical Oncology meeting 
(36). In this trial, patients were randomized to receive either 
alectinib (300 mg twice a day) or crizotinib (250 mg twice a day) 
in the first-line setting. Alectinib demonstrated significant pro-
longed PFS [median PFS not reached (95% CI: 20.3 months–not 
estimated)] compared to crizotinib [PFS: 10.2 months (95% CI: 
8.2–12.0)] (36). Although J-ALEX trial used a different dose 
than the global and North American trials, it led to FDA grant-
ing alectinib breakthrough therapy designation for first-line 
treatment (37).
FigURe 2 | Treatment algorithms for non-small cell lung cancer patients whose tumors do not have EGFR or ALK mutations (wild-type). (A) Current 
treatment algorithm. (B) Future treatment algorithm.
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Investigational Agents: Brigatinib and Lorlatinib
Brigatinib and the third-generation ALK inhibitor lorlatinib are 
being investigated for their efficacy and safety in ALK-positive 
NSCLC patients who have progressed after crizotinib and/or 
ceritinib (38, 39). Results of a phase II trial testing two doses of 
brigatinib demonstrated that patients who received the higher 
dose achieved a PFS of 12.9 months (40). As a result, the FDA 
gave brigatinib break through designation. Lorlatinib demon-
strated efficacy in a phase I study in heavily pretreated patients; 
the ORR of 46% and a PFS of 11.4 months were impressive as 
most patients had received two or more lines of previous therapy 
(41). Both agents are active in CNS disease. We look forward to 
adding these agents to the algorithm.
ROS-1
The rare ROS-1 rearrangement is now recognized as a standard 
biomaker in many countries, and several ALK inhibitors includ-
ing crizotinib show activity in these patients. In May 2016, crizo-
tinib was approved in the United States for patients with ROS-1 
rearranged NSCLC (42).
MUTATiOn STATUS negATive (“wiLD-
TYPe/wiLD-TYPe”) nSCLC
First-line Therapy: Platinum Doublet
Patients with advanced NSCLC whose tumors do not have EGFR 
mutations or ALK rearrangements, or who have unknown muta-
tion status, receive the standard of care: a platinum doublet (pem-
etrexed-based preferred) for four to six cycles (see Figure 2A). 
The Scagliotti trial demonstrated that NSCLC patients with 
adenocarcinoma experience greater benefit when treated with 
cisplatin/pemetrexed than with cisplatin/gemcitabine in the first 
line [OS: 12.6 versus 10.9 months; HR: 0.84 (95% CI: 0.71–0.99); 
p = 0.033] (1, 43).
Maintenance Therapy
Maintenance therapy is administered after completion of first-
line therapy but before disease progression. The PARAMOUNT 
trial demonstrated that pemetrexed maintenance after first-line 
chemotherapy significantly reduced disease progression over 
placebo for patients with non-squamous tumor histology (44). 
Studies have shown that pemetrexed improves both PFS and 
OS when administered as maintenance therapy (45). Although 
erlotinib was also an accepted option for switch maintenance 
based on the SATURN trial (46), the IUNO trial (HR: 1.02; 
95% CI: 0.85–1.22; p = 0.82) did not support these results. As a 
consequence, erlotinib is no longer considered as a maintenance 
option for people with negative or unknown tumor mutation 
status (47).
Second-line Therapy: immune  
Checkpoint inhibitors
The most important change in the NSCLC treatment paradigm 
has been the introduction and success of PD-L1 immune check-
point inhibitors. The programmed cell death receptor (PD-1) 
is an inhibitory receptor on T  lymphocytes that binds PD-L1 
and PD-L2 ligands. When ligands PD-L1 and PD-L2 bind, 
the immune response is suppressed. PD-L1 overexpression by 
tumor cells allows them to escape T cell detection. Monoclonal 
antibodies targeting PD-1 or PD-L1 can lead to reactivation of 
the T  lymphocyte and stimulate the natural immune response 
against tumor cells. Patients tested for PD-L1 overexpression can 
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be categorized into PD-L1 expressers (≥1% expression) and non-
expressers (<1% expression).
Trials evaluating three immunotherapy agents targeting the 
PD-1 pathway in NSCLC patients have demonstrated durable 
clinical activity and manageable toxicity (48–51).
Pembrolizumab
The KEYNOTE 010 trial compared pembrolizumab, a PD-1 
monoclonal antibody, to docetaxel in the second-line NSCLC 
setting. The trial was positive for OS, favoring pembrolizumab at 
10.4 months as compared to docetaxel at 8.5 months (HR: 0.71; 
p = 0.0008) (52). This trial included only patients whose tumors 
tested positive (> 1%) for the biomarker PD-L1. Pembrolizumab 
is administered intravenously every 3 weeks.
Nivolumab
Nivolumab, a monoclonal antibody against PD-1, was the 
first checkpoint inhibitor to show efficacy in a randomized 
phase III trial. The CHECKMATE 057 randomized phase III 
trial compared the efficacy of nivolumab with docetaxel as 
second-line treatment for patients with non-squamous NSCLC. 
Results showed OS benefits favoring nivolumab, at 12.2 months 
compared to 9.4  months for docetaxel (HR: 0.73; p =  0.0015) 
(53). Although survival was independent of whether the PD-L1 
biomarker was present, there was a positive relationship between 
the degree of positivity of the biomarker and the level of benefit 
of the drug. Nivolumab is administered intravenously (3 mg/kg) 
every 2 weeks.
The decision about which antibody to use in the second line 
will depend on many factors. Determining the level of PD-L1 
expression is complex. Biomarker testing and results, scheduling 
of drug administration (every 2 or every 3 weeks), cost, and avail-
ability all play a role.
Third-Line Therapies and Beyond
Now that checkpoint inhibitors are used in the second line, 
the previously second-line therapies become third-line options 
for patients whose tumors are mutation negative or mutation 
unknown. Options include docetaxel (54), erlotinib (55), and 
pemetrexed (56). Pemetrexed can only be prescribed if it was not 
used in first line or maintenance therapy. The REVEL trial showed 
a benefit of adding the angiogenesis inhibitor ramucirumab to 
docetaxel, with PFS of 10.5 months for the combination versus 
9.1 months for docetaxel alone (HR: 0.86; p = 0.23) (57).
It follows from above that fourth line therapies may include 
whatever agents were not administered in previous lines. 
A significant limitation of therapy selection is that no trials have 
tested these different agents in later lines of therapy. Patients 
with satisfactory performance status can be considered for clini-
cal trials.
Future Algorithm for Speculation Only
With many investigational agents in development, it is enticing 
to speculate what future treatment algorithms for patients with 
non-squamous NSCLC, mutation negative, or unknown muta-
tion status (see Figure 2B).
High PD-L1 Expressers: Checkpoint  
Inhibitors in First-line Treatment
Recently, immune checkpoint inhibitors were tested in the first-
line setting. The KEYNOTE O24 trial randomized patients whose 
tumors expressed >50% PD-L1 to pembrolizumab or a platinum 
doublet. The primary endpoint of PFS was met with 10.3 months 
favoring pembrolizumab, as compared to 6.0 months for chemo-
therapy (HR: 0.50; p < 0.001) (58). KEYNOTE 024 results will 
quickly be accepted due to the checkpoint inhibitor’s unique 
mechanism of action and low toxicity profile; we anticipate using 
pembrolizumab in the first line soon.
This contrasts with the results of the CHECKMATE 026 first-
line trial of nivolumab, which randomized patients whose tumors 
expressed >5% PD-L1 to either nivolumab or a platinum doublet. 
The primary endpoint of PFS was not met, with 5.9 months favor-
ing chemotherapy as compared to 4.2  months for nivolumab 
(HR: 1.15; p = 0.2511) (59).
For the high PD-L1 expressers, we speculate that second-line 
treatment will be a platinum doublet.
Low PD-L1 Expressers
In the future, patients who are low PD-L1 expressers will 
likely be treated with a platinum doublet in the first line. 
After progression, patients will be subdivided further based 
on the results of their initial PD-L1 test. In addition to 
pembrolizumab or nivolumab, many other agents are also in 
development.
Atezolizumab
Atezolizumab is a PD-L1 monoclonal antibody. The results of the 
OAK second-line trial comparing atezolizumab with docetaxel in 
patients with positive or negative PD-L1 expression were recently 
presented (60). The endpoint of OS was met, with results favoring 
atezolizumab at 13.8 months as compared to 9.6 months for doc-
etaxel (HR: 0.73; p = 0.0003) (60). Atezolizumab is administered 
intravenously at a dose of 1200 mg/kg, every 3 weeks.
While speculating on the future of targeted therapy, will PD-1/
PD-L1 checkpoint inhibitors will be prescribed for patients whose 
tumors are driven by EGFR mutations or ALK rearrangements? 
None of the immune therapy agents tested in the CHECKMATE 
057 (59), KEYNOTE 010 (52), or OAK (60) trials showed efficacy 
in these patients. One reason for this may be because tumors 
with driver mutations have a low mutational load and low PD-L1 
expression.
COnCLUSiOn
Treatment algorithms for NSCLC have changed dramatically 
over the last few years. Researchers continue to elucidate many 
molecular pathways involved in thoracic malignancy. Our under-
standing of tumor mutations and their contribution to therapeu-
tic efficacy is expanding. The treatment selection is complex, with 
many new target therapies being developed.
For patients with EGFR-driven tumors, treatment with 
osimertinib, a third-generation inhibitor, can lead to improve-
ments in survival in patients whose tumors have acquired 
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a T790M mutation. For patients with ALK-driven tumors 
who have progressed on crizotinib, new treatment options 
to improve survival include second-generation inhibitors 
ceritinib and alectinib. For patients without driver mutations 
or have an unknown tumor mutation status, chemotherapy 
remains the standard first-line treatment. The efficacy of 
checkpoint inhibitors has revolutionized treatment in the 
second-line setting; they now occupy the second-line setting 
and, on completion of KEYNOTE 024, we hope to see them in 
the first-line setting as well.
Targeted therapies are shifting the treatment paradigms 
and increasing survival for patients with NSCLC, a group that 
used to have a very poor prognosis. The ultimate winner is the 
patient.
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